Hematological Malignancies

First page Previous page 109 Next page Last page

Maintenance in DLBCL

• Rituximab

– 3 studies  No benefit

• Enzastaurin

– 2 studies  No benefit

• Lenalidomide

– 2 studies  Possible benefit

Made with